Mustang Bio (NASDAQ: MBIO) has appointed Martina Sersch to serve as chief medical officer. Sersch comes to New York-based Mustang from Amgen (NASDAQ: AMGN), where she was executive director. Mustang is developing cell therapies to treat cancer and gene therapies to treat rare, genetic disorders.
From Our Editors · Special Report
The AI, Big Data, and R&D Boom
From Our Editors · Podcast
Becoming the Cell & Gene Therapy Hub
Sponsored · Webinar
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
Eurofins DiscoverX
